IMHO If Medicure doesn't sign a partnership to front them several million dollars then they may need to raise money in the fall to ensure there is no interuption to their business operations however if revenues from Aggrastate grow to $20m per year then MPH just may have enough operating capital to get by on till a revenue stream starts up from preliminary sales of MC-1 in the fall next year pending approval by the FDA.
Market Data 
Markets 
AI
